LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

2.26 7.62

Buy Sell

Overview

Share price change

24h

Current

Min

2.11

Max

2.3

Key metrics
By Trading Economics
Income	1.2M -31M
Sales	-70K 1.3M
EPS	-0.26
Profit margin	-2,402.848
Employees	161
EBITDA	12M -30M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+96.44% upside

Dividends
By Dow Jones
Next Earnings	10 sie 2026

Market Stats
By TradingEconomics
Market Cap	-52M 202M
Previous open	-5.36
Previous close	2.26

News Sentiment

By Acuity

77%

23%

316 / 345 Ranking in Healthcare

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 maj 2026, 16:33 UTC

Earnings

Major Market Movers

Webull Shares Slide on 1Q Loss, Soaring Costs

22 maj 2026, 21:10 UTC

Earnings

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 maj 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 maj 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

22 maj 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 maj 2026, 19:47 UTC

Earnings

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 maj 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 maj 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 maj 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22 maj 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 maj 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 maj 2026, 18:35 UTC

Acquisitions, Mergers, Takeovers

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 maj 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 maj 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22 maj 2026, 17:54 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

22 maj 2026, 17:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 maj 2026, 17:54 UTC

Market Talk

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22 maj 2026, 17:03 UTC

Market Talk

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22 maj 2026, 16:54 UTC

Market Talk

Crypto Spot Volumes Fall 14% in April -- Market Talk

22 maj 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

22 maj 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 maj 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

22 maj 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 maj 2026, 16:16 UTC

Market Talk

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22 maj 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

22 maj 2026, 15:55 UTC

Market Talk

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22 maj 2026, 15:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22 maj 2026, 15:42 UTC

Market Talk

Oil Continues as Leading Indicator for All Markets -- Market Talk

22 maj 2026, 15:35 UTC

Market Talk

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

96.44% upside

12 Months Forecast

Average 4.42 USD 96.44%

High 7 USD

Low 2.2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

316 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.